Journals / Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi / 2013 / Cilt: 27 - Sayı: 2

Effects of fixed topical drug treatment on intraocular pressure by primary open angle glaucoma

Primer açık açılı glokomda topikal sabit kombinasyon ilaç tedavilerinin göz içi basınç üzerinde etkileri

Pages
93–97
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In all groups, mean IOP values obtained in the second month showed a statistically significant decrease when compairing with those in the beginning (P

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: It was aimed to examine the effects of topical drug treatments of brimonidine tartrate 0.5%/ timolol maleate 0.2% (BTSK), latanoprost 0.005/timolol% maleate 0.5% (LTSK) maleate and dorzolamide hydrochloride 0.2%/timolol maleate 0.5% (DTSK) on intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG).
📊
Key Findings & Data:Materials and Methods: A total of 58 patients (116 eyes) with the diagnosis of POAG assigned randomly to three groups [group 1 (BTSK), n1=18 patients (34 eyes); group 2 (DTSK), n2=20 patients (34 eyes) and group 3 (LTSK), n3= 20 patients (38 eyes)] were enrolled in the Department of Ophthalmology, School of Medicine, Pamukkale University between February and July, 2009.
💡
Conclusion & Impact:In all groups, mean IOP values obtained in the second month showed a statistically significant decrease when compairing with those in the beginning (P
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: It was aimed to examine the effects of topical drug treatments of brimonidine tartrate 0.5%/ timolol maleate 0.2% (BTSK), latanoprost 0.005/timolol% maleate 0.5% (LTSK) maleate and dorzolamide hydrochloride 0.2%/timolol maleate 0.5% (DTSK) on intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG). Materials and Methods: A total of 58 patients (116 eyes) with the diagnosis of POAG assigned randomly to three groups [group 1 (BTSK), n1=18 patients (34 eyes); group 2 (DTSK), n2=20 patients (34 eyes) and group 3 (LTSK), n3= 20 patients (38 eyes)] were enrolled in the Department of Ophthalmology, School of Medicine, Pamukkale University between February and July, 2009. Mean IOP values of the patients before the initiation of drugs and two months after drugs administration were recorded and compared with each other. Results: Mean IOP values in the previous day of the drugs initiation were 22.38±2.07 mmHg for group 1, 23.12±3.01 mmHg for group 2 and 22.64± 2.81 for group 3 mmHg, respectively. The mean values of IOP obtained from the second month from group 1 to group 3 were founded as 14.32 ± 1.98, 14.51 ± 2.14 and 14.62 ± 1.84 mmHg, respectively. For all the three groups, a statistically significant difference was not determined in IOP measurements of the beginning and the second month of the study (P> 0.05). In all groups, mean IOP values obtained in the second month showed a statistically significant decrease when compairing with those in the beginning (P

Özet

Amaç: Primer açık açılı glokom (PAAG) hastalarında brimonidin tartrat %0.2/timolol maleat %0.5(BTSK), latanoprost %0.005/timolol maleat %0.5 (LTSK) ve dorzolamid hidroklorür %0.2/timololmaleat %0.5 (DTSK) topikal ilaç tedavilerinin göz içi basıncı (GİB) üzerine etkilerini incelemek amaçlandı. Gereç ve Yöntem: Pamukkale Üniversitesi Tıp Fakültesi Göz Hastalıkları Anabilim dalında Şubat-Temmuz 2009 tarihleri arasında, PAAG tanısı ile izlenen ve belirlenen ölçütlere uyantoplam 58 hasta (116 göz) rastgele atama ile; grup 1 (BTSK) için 18 hasta (34 göz), grup 2 (DTSK) için 20 hasta (34 göz) ve grup 3 (LTSK) için 20 hastaya (38 göz) ayrılarak çalışmaya alındı. Hastalarda ilaçlar başlanmadan önceki ve ilaçlar başlandıktan iki ay sonraki GİB ortalama değerleri kaydedildi ve birbiri ile kıyaslandı. Bulgular: Grup 1, grup 2 ve grup 3 için ilaçlar başlanmadan önce gün içi elde edilen tüm GİB değerlerinin ortalamaları sırası ile; 22.38±2.07, 23.12±3.01 ve 22.64± 2.81 mmHg olarak bulundu. 2. ayda elde edilen GİB değerlerinin ortalamaları ise sırasıyla; 14.32±1.98, 14.51±2.14 ve 14.62±1.84 mmHg olarak bulundu. Her üç grup için başlangıç ve 2. ayda elde edilen GİB ölçümleri arasında, istatistiksel olarak anlamlı bir fark saptanmadı (P>0.05). Her üç grupta da 2. ayda elde edilen GİB ortalamaları, başlangıçta elde edilen GİB ortalamalarına göre istatistiksel olarak ileri düzeyde anlamlı düşüş gösterdi (P

🔖

Cite This Article

YILDIRIM, C., ÖZER, M. A. (2022). Effects of fixed topical drug treatment on intraocular pressure by primary open angle glaucoma. Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi, Cilt: 27 - Sayı: 2, 93–97. https://ajindex.com/articles/514661

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Hollows FC, Graham PA. Intraocular pressure, glaucoma, and glaucoma suspects in a defined population. Br J Ophthalmol 1966; 50: 570-586
  2. Bengisu Ü. Glokom. Göz hastalıkları. Ankara: Palme Yayınları, 1998: 139-158
  3. Choudhri S, Wand M, Shields MB. A comparison of dorzolamid-timolol combination versus the concomitant drugs. Am J Ophthalmology 2000; 130: 832-833
  4. Higginbotham EJ, Feldman R, Stiles M, Dubiner H. Latanoprost and timolol combination therapy vs monotherapy: one- year randomized trial. Arch Ophthalmol 2002; 120: 915-922
  5. Quigley HA. Number of people with glaucoma wordwide. Br J Ophthalmol 1996; 80: 389-393
  6. Bengtsson B. Incidence of manifest glaucoma. Br J Ophthalmol 1989; 73: 483-487
  7. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995; 26: 233- 236
  8. Sheerwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine/ 0.5% timolol fixed combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: A 12-month randomized trial. Arch Ophthalmol 2006; 124: 1230-1238
  9. Craven ER, Walters TR, Williams R, et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3- month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005; 21: 337-348
  10. Thelen U, Buchholz P, Kimmich F. Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: Multicenter, open-label, observational study in Germany. Curr Med Res Opin 2009; 25: 1003-1009
  11. Papaconstantinou D, Georgalas I, Kourtis N, et al. Preliminary results following the use of a fixed combination of timolol-brimonidine in patients with ocular hypertension and primary open-angle glaucoma. Clin Ophthalmol 2009; 3: 227-230
  12. Ozkurt YB, Sengor T, Evciman T, et al. Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg. Clin Ophthalmol 2009; 3: 337-339
  13. Stewart WC, Stewart JA, Day DG, Sharpe ED, Jenkins JN. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy. Eye 2004; 18: 990-995
  14. Henderer JD, Wilson RP, Moster MR, et al. Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mm Hg. J Glaucoma 2005; 14: 267-270
  15. Konstas AG, Kozobolis VP, Tsironi S, et al. Comparison of